Further analyses are ongoing to confirm the potential impact using the actual Omicron variant sequence, according to the drugmaker.Regeneron Pharmaceuticals Inc. headquarters in Tarrytown, N.Y., U.S., on June 12, 2020.Michael Nagle / Bloomberg via Getty ImagesNov. 30, 2021, 11:52 AM UTC / Updated Nov. 30, 2021, 11:59 AM UTC / Source: ReutersRegeneron Pharmaceuticals said on Tuesday prior analyses…
The drugmaker said the analyses of the individual mutations present in the Omicron variant indicate “that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity.”
Further analyses are ongoing, the company said, adding that there was no direct data testing Omicron’s resistance to immunity gained from vaccines and monoclonal antibodies.
Read Full Story
NBC News Rating
Discover more from News Facts Network
Subscribe to get the latest posts sent to your email.
